Health Care · Biological Products, (No Diagnostic Substances)

GLUE Monte Rosa Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 182645790 filings
Russell 2000

GLUE at a glance

Monte Rosa Therapeutics, Inc. (GLUE, SEC CIK 1826457) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as October 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Monte Rosa Therapeutics, Inc. (GLUE) reported revenue of $123.7 million (up 63.5% from FY2024) and a net loss of $38.6 million.
  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Monte Rosa Therapeutics, Inc. (GLUE) shares worth $360.0 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Bowen Matthew on October 5, 2026 of 13 shares at $10.56 per share.
  • In the last 90 days, GLUE insiders reported 0 open-market purchases ($0) and 1 open-market sale ($137.28) on Form 4, a net sale of $137.28.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$123.7M
+63.5% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$137.28
13F holders
27 funds
$360.0M · −3 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Continued operating losses, net loss $84.8 million for nine months ended September 30, 2026
  • Cash, equivalents, restricted cash and marketable securities $582.6 million as of September 30, 2026
  • Development spending risk: Phase 2 trials for MRT-2359 and MRT-8102 increasing expenses
  • Profitability risk: accumulated deficit reached $562.1 million as of September 30, 2026

Management Discussion & Analysis

  • Quarterly collaboration revenue $54.4M, up $41.6M YoY from $12.8M
  • Net income $3.1M vs $27.1M loss YoY, operating margin (3.6%) vs (72.1%)
  • MRT-8102 largest R&D line at $5.6M, MRT-6160 lowest at $1.4M
  • Cash, equivalents, restricted cash and securities $582.6M; operating cash flow $(122.5)M
  • $323.8M net proceeds from 2026 offering; cash runway expected into 2029

AI summary of the GLUE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Full results and management commentary available in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Positive Phase 1 GFORCE-1 results: MRT-8102 achieved 80% to 90% NEK7 degradation with adverse events comparable to placebo
  • Three MRT-8102 Phase 2 studies planned: gout in Q4 2026, coronary artery disease and hidradenitis suppurativa in H1 2027
Filed Oct 1, 2026Full analysis →

Item 8.01: Other Events

  • Phase 1 GFORCE-1 enrolled 108 obese subjects, with MRT-8102 achieving 80–90% median NEK7 degradation across 5 mg, 20 mg, and 40 mg doses
  • Atherosclerosis and systemic inflammation biomarkers substantially reduced, supporting MRT-8102’s potential across NLRP3/IL-1-driven diseases

Item EX-99.1: Item EX-99.1

  • Phase 1 GFORCE-1 enrolled 108 obese subjects; MRT-8102 achieved 80–90% median NEK7 degradation across 5 mg, 20 mg, and 40 mg doses
  • ASCVD-related biomarkers declined materially, including calprotectin 56%, S100A12 46%, SAA 51%, and fibrinogen 28%

Item 7.01: Regulation FD Disclosure

  • Positive Phase 1 GFORCE-1 results for MRT-8102, an oral NEK7-directed molecular glue degrader
  • Reported normalization of key pathogenic ASCVD drivers in subjects with elevated cardiovascular disease risk

Item EX-99.2: Item EX-99.2

  • GFORCE-1 Phase 1 data support MRT-8102’s mechanism, with approximately 80%-90% sustained NEK7 degradation across doses
  • Safety favorable overall: no serious adverse events, treatment-emergent events 33% vs 30% for placebo, no serious infections
Filed Sep 8, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Novartis initiated Phase 2a/b Sjögren’s study for MRT-6160, advancing the partnered program toward dose selection for Phase 3
  • Monte Rosa to receive $50 million milestone tied to the study’s first patient visit

Item 8.01: Other Events

  • Phase 2 initiation for MRT-6160 triggered a $50 million milestone payment from Novartis
  • Novartis holds exclusive worldwide development, manufacturing, and commercialization rights

Item 7.01: Regulation FD Disclosure

  • MRT-6160 (DDY391) entered a Phase 2 study in participants with Sjögren’s disease
  • Novartis is conducting the study under its collaboration with Monte Rosa

AI summaries of GLUE 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for GLUE

Don't miss the next GLUE filing

  • Alerts as it files. A push when GLUE files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut GLUE, by share count.
  • Ask anything. An AI agent that reads every GLUE filing and answers with sources.

GLUE alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Bowen MatthewSellOct 5, 2026$10.56
Warmuth MarkusSellJul 16, 2026$23.18
Champoux JenniferMJul 15, 2026$3.98
Champoux JenniferMJul 15, 2026-
Champoux JenniferSellJul 15, 2026$23.38
Townson SharonMJul 6, 2026-
Townson SharonSellJul 6, 2026$23.25
Townson SharonSellJul 6, 2026$24.13

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$0$75.6M$123.7M
Operating Income-$143.3M-$81.1M-$54.2M
Net Income-$135.4M-$72.7M-$38.6M
Op. Margin--107.3%-43.8%
Net Margin--96.1%-31.2%
Balance Sheet
Total Assets-$438.7M$448.7M
Equity$179.3M$222.9M$233.1M
ROE-75.5%-32.6%-16.6%
Cash Flow
Operating CF-$43.8M$42.0M-$22.8M
CapEx$19.0M$4.0M$4.7M

Source: XBRL data in Monte Rosa Therapeutics, Inc. (GLUE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate GLUE share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
GLUE shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$360.0M
Q2 202630$754.1M
Q1 202632$449.6M
Q4 202523$331.0M
Q3 202525$157.4M
Q2 202525$103.9M
Q1 202521$59.3M
Q4 202418$94.1M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 201 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

GLUE filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
4Oct 6, 2026--
8-KOct 1, 2026Analysis-
8-KSep 8, 2026Analysis-
SC 13GAug 14, 2026-
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
4Jul 17, 2026--
4Jul 16, 2026--
4Jul 7, 2026--
4Jul 6, 2026--
4Jul 1, 2026--
4Jun 30, 2026--
4Jun 30, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--

Related Health Care companies

All Health Care →

GLUE SEC filings: frequently asked questions

Are GLUE insiders buying or selling?

In the last 90 days, Monte Rosa Therapeutics, Inc. (GLUE) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $137 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold GLUE stock?

As of September 30, 2026, the largest Monte Rosa Therapeutics, Inc. (GLUE) holders among the 13F filers tracked by SignalX were T. Rowe Price Group ($87.8 million), BlackRock ($85.8 million), State Street Corp ($44.4 million), Vanguard Capital Management LLC ($41.5 million), Dimensional Fund Advisors ($16.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was GLUE's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Monte Rosa Therapeutics, Inc. (GLUE) reported revenue of $123.7 million (up 63.5% from FY2024) and a net loss of $38.6 million. The figures come from the XBRL data in the 10-K.

What did GLUE report in its latest 8-K?

Monte Rosa Therapeutics, Inc. (GLUE) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.

What are the latest GLUE SEC filings?

Monte Rosa Therapeutics, Inc. (GLUE) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on October 6, 2026.

What is GLUE's SEC CIK number?

Monte Rosa Therapeutics, Inc. (GLUE)'s SEC Central Index Key (CIK) is 1826457. EDGAR lists every GLUE filing under that number.

Ask anything about GLUE

The research agent reads GLUE's filings, financials, insider trades and 13F holders, then answers with sources.